Sector News

Regeneron tops best science employer poll again

October 17, 2014
Life sciences
Regeneron has once again come top of Science magazine’s top 20 employers survey, followed by Novo Nordisk and Roche’s Genentech unit.
 
The poll is based on 5,394 responses from readers of Science and employees in the biotechnology and pharmaceutical industry, who were asked to rank the best employers on a number of characteristics. The categories included ‘’innovative leader in the industry’, treats employees with respect’, ‘has loyal employees’ and ‘is socially responsible’.
 
Regeneron came out as the top company for the third year in a row, while Novo leapt to second from 11th place last year. They were followed by Genentech, Vertex (4), Eli Lilly (5), AbbVie (7) and Roche itself, up eight places from last year to eighth.
 
Biogen Idec came in at 10th, while Novartis slipped three places to 11th. Newcomers to the list were Actelion (14), Johnson & Johnson (19) and Merck KGaA (20). The other pharma players in the top 20 are Boehringer Ingelheim (13, down from 9), Celgene (up two places to 15), Bayer (up four to 16) and Amgen, which rose one place to 18th.
 
Science claims that “a common thread runs through the top 20 list: give employees the intellectual freedom and support necessary to pursue high-risk/high-reward goals – and they’ll deliver”. The journal says that by adding “a noble mission” to this, “employers can create a positive feedback loop that maximises employees’ drive and dedication as well as company profits”.
 
By Kevin Grogan
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]